Employees: 02 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2012-07-16 (13 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: OIGNIES (62590), Pas-de-Calais
PHARMACIE VANHOVE-DEPONTHIEUX : revenue, balance sheet and financial ratios
PHARMACIE VANHOVE-DEPONTHIEUX is a French company
founded 13 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in OIGNIES (62590),
this company of category PME
shows in 2022 a revenue of 1.9 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE VANHOVE-DEPONTHIEUX (SIREN 752737452)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
1 924 594 €
N/C
N/C
N/C
1 581 991 €
N/C
1 515 091 €
Net income
49 440 €
64 276 €
136 872 €
171 284 €
69 664 €
98 206 €
71 869 €
95 326 €
72 637 €
EBITDA
N/C
N/C
182 895 €
N/C
N/C
N/C
106 356 €
N/C
152 566 €
Net margin
N/C
N/C
7.1%
N/C
N/C
N/C
4.5%
N/C
4.8%
Revenue and income statement
In 2024, PHARMACIE VANHOVE-DEPONTHIEUX generates positive net income of 49 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 73 k€ -> 49 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
49 440 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 20%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 77%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
19.647%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
77.29%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
205.561
163.907
137.654
110.501
81.553
61.255
43.591
28.986
19.647
Financial autonomy
30.783
35.463
40.162
44.57
52.04
57.324
65.69
71.833
77.29
Repayment capacity
14.278
None
13.41
None
None
None
3.644
None
None
Cash flow / Revenue
6.132%
None%
5.272%
None%
None%
None%
8.009%
None%
None%
Sector positioning
Debt ratio
19.652024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Good-8 pts over 3 years
In 2024, the debt ratio of PHARMACIE VANHOVE-DEPONTH... (19.65) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
77.29%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Excellent+7 pts over 3 years
In 2024, the financial autonomy of PHARMACIE VANHOVE-DEPONTH... (77.3%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
3.64 years2022
2022
Q1: 1.29 years
Med: 3.55 years
Q3: 6.63 years
Average
In 2022, the repayment capacity of PHARMACIE VANHOVE-DEPONTH... (3.64) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 342.95. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
427.977
414.209
564.762
452.041
423.527
387.736
514.192
376.955
342.954
Interest coverage
29.759
None
9.589
None
None
None
2.133
None
None
Sector positioning
Liquidity ratio
342.952024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Excellent
In 2024, the liquidity ratio of PHARMACIE VANHOVE-DEPONTH... (342.95) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
2.13x2022
2022
Q1: 0.74x
Med: 2.5x
Q3: 5.15x
Average
In 2022, the interest coverage of PHARMACIE VANHOVE-DEPONTH... (2.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE VANHOVE-DEPONTHIEUX
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
307 124 €
0 €
298 474 €
0 €
0 €
0 €
175 850 €
0 €
0 €
Inventory turnover (days)
25
0
24
0
0
0
21
0
0
Customer payment term (days)
7
0
8
0
0
0
6
0
0
Supplier payment term (days)
34
0
22
0
0
0
22
0
0
Positioning of PHARMACIE VANHOVE-DEPONTHIEUX in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE VANHOVE-DEPONTHIEUX is estimated at
690 218 €
(range 480 657€ - 1 032 607€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
480k€690k€1032k€
690 218 €Range: 480 657€ - 1 032 607€
NAF 5 année 2024
Valuation method used
Net Income Multiple
49 440 €
×
14.0x
=690 219 €
Range: 480 658€ - 1 032 607€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE VANHOVE-DEPONTHIEUX with other companies in the same sector:
Frequently asked questions about PHARMACIE VANHOVE-DEPONTHIEUX
What is the revenue of PHARMACIE VANHOVE-DEPONTHIEUX ?
The revenue of PHARMACIE VANHOVE-DEPONTHIEUX in 2022 is 1.9 M€.
Is PHARMACIE VANHOVE-DEPONTHIEUX profitable?
Yes, PHARMACIE VANHOVE-DEPONTHIEUX generated a net profit of 49 k€ in 2024.
Where is the headquarters of PHARMACIE VANHOVE-DEPONTHIEUX ?
The headquarters of PHARMACIE VANHOVE-DEPONTHIEUX is located in OIGNIES (62590), in the department Pas-de-Calais.
Where to find the tax return of PHARMACIE VANHOVE-DEPONTHIEUX ?
The tax return of PHARMACIE VANHOVE-DEPONTHIEUX is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE VANHOVE-DEPONTHIEUX operate?
PHARMACIE VANHOVE-DEPONTHIEUX operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart